<DOC>
	<DOCNO>NCT02850822</DOCNO>
	<brief_summary>Allogeneic hematopoietic stem cell transplantation ( allo-HSCT ) appear efficient tool cure refractory anemia excess blasts-1 ( RAEB-1 ) , refractory anemia excess blasts-2 ( RAEB-2 ) acute myeloid leukemia ( AML ) secondary myelodysplastic syndrome ( MDS ) . At present , necessity chemotherapy pre-transplantation RAEB-1 , RAEB-2 AML secondary MDS ( bone marrow blast cell less 50 % ) undergoing allo-HSCT remains discussion . In study , safety efficacy chemotherapy chemotherapy pre-transplantation patient RAEB-1 , REAB-2 AML secondary MDS ( bone marrow blast cell less 50 % ) undergo allo-HSCT evaluate .</brief_summary>
	<brief_title>Effect Chemotherapy v No Chemotherapy Pre-transplant MDS Undergoing Allo-HSCT</brief_title>
	<detailed_description>Allo-HSCT appear efficient tool cure patient MDS AML secondary MDS . Decitabine and/or chemotherapy pre-transplantation could reduce blast cell bone marrow improve complete remission rate . However , decitabine and/or chemotherapy side effect might increase treatment-related mortality . At present , necessity chemotherapy pre-transplantation RAEB-1 , RAEB-2 AML secondary MDS ( bone marrow blast cell less 50 % ) undergoing allo-HSCT remains discussion . In study , safety efficacy chemotherapy chemotherapy pre-transplantation patient RAEB-1 , REAB-2 AML secondary MDS ( bone marrow blast cell less 50 % ) undergo allo-HSCT evaluate .</detailed_description>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>RAEB1 , REAB2 AML Secondary MDS ( Bone marrow blast cell less 50 % ) undergoing alloHSCT 1465 year Any abnormality vital sign ( e.g. , heart rate , respiratory rate , blood pressure ) Patients condition suitable trial ( investigator ' decision )</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>decitabine</keyword>
	<keyword>chemotherapy</keyword>
</DOC>